title: Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
authors.affiliation: Y. Tony Yang, George Mason University, Fairfax, VA; and Brian Chen and Charles L. Bennett, University of South Carolina, Columbia, SC.
authors.forename: Y Tony
authors.initials: YT
authors.lastname: Yang
authors.affiliation: Y. Tony Yang, George Mason University, Fairfax, VA; and Brian Chen and Charles L. Bennett, University of South Carolina, Columbia, SC.
authors.forename: Brian
authors.initials: B
authors.lastname: Chen
authors.affiliation: Y. Tony Yang, George Mason University, Fairfax, VA; and Brian Chen and Charles L. Bennett, University of South Carolina, Columbia, SC.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence*; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D033161:Government Regulation; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence*; D006801:Humans; D008489:Medical Indigency / Q000331:legislation & jurisprudence; D017057:Medically Uninsured / Q000331:legislation & jurisprudence; D009965:Orphan Drug Production / Q000191:economics / Q000331:legislation & jurisprudence*; D011050:Policy Making; D014481:United States; D014483:United States Dept. of Health and Human Services / Q000331:legislation & jurisprudence*; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*